-
Press Release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
-
Story
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026 -
Press Release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
-
Story
The Day AI Made Me Rethink What Science Could Do -
Press Release
Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
-
Press Release
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
-
Story
Smarter decisions at scale: How Novartis is using AI to advance R&D -
Story
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next -
Press Release
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
-
Press Release
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
-
Press Release
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
-
Press Release
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients